UNSPSC 51271612: Levobupivacaine

This classification denotes an anesthetic agent with the molecular formula C18H28N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A5H73K9U3W, chemically known as 2,6-pipecoloxylidide, 1-butyl-, l-(-)- but generally known as levobupivacaine, which bears US NIH Compound Identifier 92253. European Medicines Agency schedules Levobupivacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08464MIG.

UNSPSC 51271612 Levobupivacaine is a Commodity code representing a specific local anesthetic pharmaceutical product procured through state and local cooperative purchasing agreements and health system contracts. State and local government buying under this code centers on acquiring generic and branded levobupivacaine in multiple strengths and formulations—injectable solutions, epidural and spinal preparations, and regional anesthesia kits—for use across hospitals, surgical centers, emergency departments, and outpatient facilities within participating jurisdictions. Issuing bodies include state cooperative purchasing alliances, state health departments, individual state agencies, counties, municipalities, hospital systems, and special-purpose health districts. Single-source and multi-award contracts are common, often restricted to vendors meeting FDA manufacturing compliance, Drug Supply Chain Security Act (DSCSA) certification, and supply chain security requirements. Purchasing typically flows through authorized pharmaceutical wholesalers rather than direct-to-end-user arrangements, with pricing evaluated on net wholesale cost formulas, WAC-minus discounts, or fixed-price schedules negotiated for contract terms of one to three years.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon. This representative opportunity sought manufacturers and authorized distributors to supply comprehensive pharmaceutical portfolios—including levobupivacaine and related anesthetics—through three mandated wholesalers (AmerisourceBergen / Cencora, Cardinal Health, and Morris & Dickson), with awards effective July 1, 2026. Vendors faced evaluation weighted heavily to price competitiveness (75 percent), with smaller weightings on fixed pricing structure (10 percent), EDI capability (5 percent), administrative fee compliance (5 percent), and data format requirements (5 percent). Mandatory insurance requirements included $5 million general liability and $2 million network security / privacy liability per occurrence. The contract term spans two years for new vendors with optional extensions, or alignment with existing agreement expiration dates through June 30, 2028 for incumbent responders.